TABLE OF CONTENTS
KEY
🔍 | Deep Dive |
📌 | Clinical Application |
🔸 | Weak Evidence |
🔹 | Strong Evidence |
📑 | Evidence summaries |
✅ | Recommended treatment |
⚠️ | Critical Information |
💡 | Extra Reading |
❗ | Caveats |
This blog post started as a heated debate with a cardiology fellow.
“Is SCAPE a real clinical entity, or just a dramatic name for severe acute heart failure?”
Let’s break it down.
I first heard the term SCAPE on an EMcrit blog, and like any true emergency physician, I was instantly hooked. There’s something about a sharp, catchy term that captures a chaotic ED presentation so perfectly and before long, I was using it in daily practice.
But what even is SCAPE?
It is “Sympathetic Crashing Acute Pulmonary edema”
SCAPE is best understood as a subset of acute heart failure syndrome (AHFS), where sympathetic activation plays a central role in a rapidly evolving, life-threatening presentation.
It overlaps with terms we already use, such as acute pulmonary edema, crashing pulmonary edema, and acute decompensated heart failure [1].
Because sympathetic overactivity plays a central role in these patients, the term SCAPE better describes this rapidly developing, life-threatening form of pulmonary edema.
AHFS itself is defined by elevated cardiac filling pressures leading to accumulation of fluid in the pulmonary interstitium and alveoli.
The ESC 2021 guidelines on heart failure define AHFS as a rapid or gradual onset of symptoms and/or signs of heart failure severe enough to require urgent medical attention, leading to an unplanned hospital admission or emergency department visit [2].
AHFS includes:
- Acutely decompensated heart failure
- Acute pulmonary edema
- Isolated right ventricular failure
- Cardiogenic shock
This spectrum ranges from relatively stable congestion to critically unwell patients.
SCAPE lies at the severe, rapidly progressive end of this spectrum. These patients develop symptoms over minutes to hours, often presenting with sudden respiratory distress and significant hemodynamic disturbance.
The key feature is the speed of onset and progression, which leaves a very limited window for intervention.
What is different here?
At baseline, pulmonary fluid balance is tightly regulated, a balance between forces pushing fluid into the alveoli and mechanisms clearing it.
In acute heart failure, increased cardiac filling pressures are transmitted back to the pulmonary circulation, leading to:
- Capillary distension
- Interstitial edema
- Eventually, alveolar flooding and hypoxia
This progression is usually stepwise.
SCAPE follows the same pathway but not at the same pace.
SCAPE evolves over minutes to hours, not days. The key change is a sudden sympathetic surge on top of an already vulnerable myocardium.
That surge leads to:
- Marked increase in heart rate
- Reduced diastolic filling time
- Increased afterload
- Activation of RAAS
- Rapid rise in left-sided pressures
Fluid also rapidly shifts from the splanchnic circulation into the lungs, worsening congestion even without major total-body fluid overload.
The result is a rapid shift from compensated physiology to overt pulmonary edema, with severe hypoxia and respiratory distress 1.
This is why SCAPE behaves differently from typical fluid-overload pulmonary edema (FOPE). The issue is not just excess fluid, but where the fluid is and how quickly it got there.
So how do we identify SCAPE?
Clinical Features
The term itself tells you what to look for
- “Sympathetic” crashing acute pulmonary edema
- Hypertension (typically SBP >160 mmHg and/or MAP >120 mmHg)
- Other features of sympathetic activation
- Diaphoresis
- Pallor, looking acutely unwell
- Tachycardia
- Agitation
SCAPE is essentially a form of hypertensive acute heart failure, so high systolic pressures are the rule.
- Sympathetic “crashing” acute pulmonary edema
- Marked dyspnea, tachypnea, and hypoxemia
- Sympathetic crashing “acute” pulmonary edema
- Rapid onset
- Symptoms evolve quickly ( usually<6hrs)
- Sympathetic crashing acute “pulmonary edema”
- Diffuse rales on auscultation
- Pink frothy sputum may be present
Other components that you may or may not see are
- Recurrent episodes.
- Usually, there is a trigger and an underlying cardiac condition.
ESC 2021 guidelines on heart faliure mention that AHF may present as a first occurrence or, more frequently, as a consequence of acute decompensation of chronic HF, and may be caused by primary cardiac dysfunction or precipitated by extrinsic factors [2].
Underlying cardiac condition
- Chronic left ventricular failure
- History of hypertension
Renal artery stenosis is strongly associated with SCAPE. It is classically described as Pickering syndrome, where renovascular hypertension precipitates recurrent episodes of flash pulmonary edema.
Acute triggers
- acute Coronary syndrome
- Hypertensive emergency
- Arrythmia
- Mechanical causes
- Pulmonary embolism
- Infection
- cardiac Tamponade
Also watch for,
- Volume overload
- Sympathomimetic intoxication
- Withdrawal
- Exertion, stress, or anxiety
Not every patient with respiratory distress and hypertension has SCAPE. That combination is common and not specific.
Point of Care Tests
POCUS
- Lung ultrasound
- Diffuse B-lines across the lung fields
- Thin pleural interface
This pattern is typical of cardiogenic pulmonary edema. In contrast, non-cardiogenic causes usually produce a more patchy distribution of B-lines, often accompanied by pleural irregularities and subpleural consolidations.
In very early presentations, lung ultrasound can still be normal.
- Cardiac ultrasound
- Reduced ejection fraction or
- Features suggesting diastolic dysfunction
- IVC
- Not reliable here patients may be hypo-, eu-, or hypervolemic
Natriuretic peptides
- Can be unexpectedly low in some cases, especially in hyper-acute presentations or advanced disease
How do we treat it?
SCAPE develops as a vicious cycle.
A sudden sympathetic surge causes severe vasoconstriction, increased afterload, and rapid shifting of fluid into the lungs, leading to flash pulmonary edema and severe respiratory distress.
The resulting hypoxia and anxiety further increase sympathetic activity, causing the patient to deteriorate rapidly unless the cycle is quickly broken with NIV and aggressive vasodilation.
Four core principles help us break this cycle.
1. Positive pressure comes first
- The most important intervention in SCAPE is early non-invasive ventilation, either CPAP or BiPAP, both of which have comparable efficacy.
- Positive airway pressure reduces both preload and afterload, with higher pressures producing greater and faster hemodynamic benefit.
- BiPAP offers an additional advantage in severely orthopneic patients by reducing the work of breathing during inspiration.
A common mistake in SCAPE management is failing to adequately up-titrate CPAP or BiPAP settings. Increasing airway pressure can improve preload and afterload almost instantly often faster than medications.
- From an evidence-based perspective, NIV is the most important early intervention in SCAPE. It reduces the need for endotracheal intubation, lowers mortality in cardiogenic pulmonary edema, and helps avoid complications associated with invasive mechanical ventilation [3, 4, 5, 6]
The 3CPO trial, a multicenter randomised controlled trial, demonstrated that both CPAP and NIPPV safely provide earlier improvement in breathlessness, respiratory distress, and metabolic abnormalities in acute cardiogenic pulmonary edema [7].
What about HFNC?
HFNC is not considered first-line therapy in SCAPE or acute cardiogenic pulmonary edema.
HFNC may still have a role in selected patients who cannot tolerate CPAP or BiPAP. It helps by reducing upper airway dead space, improving FiO₂ delivery, and providing a small amount of PEEP.
A small observational study from 2019 compared HFNC to intubation in patients with acute CHF and found that they had similar outcomes. Also, 87% of acute CHF patients treated with HFNC improved without requiring intubation [8].
In patients with acute heart failure and worsening hypoxemia, NIV comes first. HFNC can be considered when CPAP/BiPAP is poorly tolerated, particularly as a strategy to avoid intubation.
2. Blood pressure control
- Severe hypertension increases left ventricular afterload, worsening fluid backup into the lungs, a key mechanism in SCAPE. Rapid blood pressure reduction is therefore a major treatment goal.
- There is no strict blood pressure target, but AHA guidance on hypertensive emrgencies aims to rapidly bring the systolic BP down to around <140 mmHg [9].
The nitroglycerin doses required in SCAPE are often much higher than those used for angina.
Lower doses mainly cause venodilation, while the high doses used in SCAPE are needed to achieve significant arterial vasodilation and afterload reduction.
3. Avoid Beta-Blockers
2017 AHA guidelines on hypertension management consider beta-blockers contraindicated in acute pulmonary edema [10].
- Beta-blockers can worsen acute cardiogenic pulmonary edema by reducing cardiac contractility and impairing pump function.
- In SCAPE, where the failing left ventricle is already struggling against a markedly elevated afterload, further reducing contractility may worsen pulmonary edema and hemodynamic instability.
4. Recognise When the SCAPE Breaks
- With appropriate treatment, SCAPE often improves dramatically within minutes as the cycle of sympathetic surge, severe hypertension, and pulmonary edema is interrupted.
- One of the clearest signs that the SCAPE is “breaking” is a rapid fall in blood pressure accompanied by improvement in respiratory distress.
Management at this stage involves:
- Quickly down-titrating the nitroglycerin infusion and CPAP/BiPAP settings while watching closely for recurrence of symptoms.
- Identifying and treating the trigger to prevent relapse.
SCAPE usually occurs due to a combination of an underlying cardiac condition and an acute precipitating trigger. Identifying these factors is important, as some may require specific treatment to prevent recurrence and improve outcomes.
So, how to actually do all this?
To boil it down
- Start non-invasive ventilation early. Begin with a PEEP of 6 and rapidly titrate up as needed.
- Start a nitroglycerin infusion. One commonly used approach is a high-dose loading phase of 600 - 1000 mcg, followed by a lower maintenance infusion that is titrated according to response.
- With appropriate treatment, SCAPE often improves rapidly with falling blood pressure and dramatic improvement in respiratory distress.
- As the patient improves, nitroglycerin and NIV settings can usually be weaned down quickly.
Within 10 minutes, the patient should look significantly better.
Other drugs to consider
Now, anticipating the next question:
Morphine
Morphine was once routinely used in acute pulmonary edema, but current evidence does not support its use in SCAPE.
An analysis from the ADHERE registry by W. Frank Peacock found that IV morphine in acute decompensated heart failure was associated with increased morbidity and mortality [11].
More recently, the MIMO trial, a prospective randomised study comparing morphine with midazolam in acute pulmonary edema, was stopped early because of harm in the morphine group, including higher rates of shock and cardiac arrest [12].
At present, opioids should generally be avoided in SCAPE unless there is another clear indication.
So what if my patient is “Mask Intolerant”?
There are a few ways to improve NIV tolerance.
But first, remember: in SCAPE, agitation is usually driven by hypoxia. Fixing oxygenation often fixes the agitation.
- Reassure the patient.
- Introduce the mask gradually, don’t force it on suddenly.
- Start with lower pressures and slowly increase them.
- If needed, use mild sedation (low-dose benzodiazepines, haloperidol, or dexmedetomidine).
- If NIV fails, consider HFNC or intubation.
Furosemide
Furosemide plays a role, but it is not the immediate lifesaving intervention in SCAPE.
In the early phase, the priority is rapid afterload reduction and positive pressure ventilation. Renal perfusion is often poor during the initial sympathetic surge, meaning diuretics may not work effectively right away.
A practical approach is to first stabilise the patient with NIV and nitroglycerin, then introduce IV furosemide once perfusion improves if there is clear evidence of volume overload.
ACEi and ARB
ACE inhibitors and ARBs can help reduce afterload once the patient is stabilised. However, early use in unstable SCAPE patients may increase the risk of hypotension and acute kidney injury. As a result, they generally have no significant role in the initial ED management of SCAPE.
What Matters…
Ask these 3 questions to identify SCAPE
1️⃣ Is there severe hypertension?
(typically SBP >160 mmHg and/or MAP >120 mmHg)
SCAPE is essentially a form of hypertensive acute heart failure, so high systolic pressures are the rule.
Other features of sympathetic activation are
- Diaphoresis
- Pallor
- Looking acutely unwell
- Tachycardia
- Agitation
2️⃣ Is the patient acute and crashing?
Symptoms evolve rapidly ( usually<6hrs) with severe respiratory distress and hypoxemia.
Due to intense sympathetic activation, severe vasoconstriction and rapid splanchnic fluid redistribution occur, leading to sudden “flash pulmonary edema.”
3️⃣ Is this pulmonary edema?
Elevated left-sided filling pressures rapidly transmit back to the pulmonary circulation, causing alveolar flooding and hypoxemia.
Examination:
- Diffuse rales on auscultation
- Pink frothy sputum may be present
Point of Care Tests
- Lung ultrasound → Diffuse B-lines across the lung fields.
- Cardiac ultrasound → Reduced ejection fraction or features suggesting diastolic dysfunction.
- IVC → Not reliable here.
- Natriuretic peptides → Can be unexpectedly low in hyper-acute presentations.
If the answer is yes to all three, treat it like SCAPE → because the window to break the cycle is small.
- Agrawal, Naman, et al. "Sympathetic crashing acute pulmonary edema." Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of Critical Care Medicine 20.12 (2016): 719.
- Masip, Josep, et al. "Acute heart failure in the 2021 ESC heart failure guidelines: a scientific statement from the Association for Acute CardioVascular Care (ACVC) of the European Society of Cardiology." European Heart Journal Acute Cardiovascular Care 11.2 (2022): 173-185.
- Agarwal, R., et al. "Non-invasive ventilation in acute cardiogenic pulmonary oedema." Postgraduate medical journal 81.960 (2005): 637-643.
- Kelly, C. A., et al. "Randomised controlled trial of continuous positive airway pressure and standard oxygen therapy in acute pulmonary oedema. Effects on plasma brain natriuretic peptide concentrations." European heart journal 23.17 (2002): 1379-1386.
- Crane, S. D., et al. "Randomised controlled comparison of continuous positive airways pressure, bilevel non-invasive ventilation, and standard treatment in emergency department patients with acute cardiogenic pulmonary oedema." Emergency medicine journal 21.2 (2004): 155-161.
- Collins, Sean P., et al. "The use of noninvasive ventilation in emergency department patients with acute cardiogenic pulmonary edema: a systematic review." Annals of emergency medicine 48.3 (2006): 260-269.
- Gray, A. J., et al. "A multicentre randomised controlled trial of the use of continuous positive airway pressure and non-invasive positive pressure ventilation in the early treatment of patients presenting to the emergency department with severe acute cardiogenic pulmonary oedema: the 3CPO trial." Health Technology Assessment 13.33 (2009): 1-106.
- Kang, Min Gyu, et al. "Clinical efficacy of high-flow oxygen therapy through nasal cannula in patients with acute heart failure." Journal of Thoracic Disease 11.2 (2019): 410.
- Bress, Adam P., et al. "The management of elevated blood pressure in the acute care setting: a scientific statement from the American Heart Association." Hypertension 81.8 (2024): e94-e106.
- Whelton, Paul K., et al. "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines." Journal of the American College of Cardiology 71.19 (2018): e127-e248.
- Peacock, W. F., et al. "Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis." Emergency Medicine Journal 25.4 (2008): 205-209.
- Dominguez-Rodriguez, Alberto, et al. "Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled trial." European Journal of Heart Failure 24.10 (2022): 1953-1962.
Made with Bullet